Amgen [AMGN] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Amgen

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Amgen wins in 9 metrics, Johnson & Johnson wins in 11 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricAmgenJohnson & JohnsonBetter
P/E Ratio (TTM)22.3319.24Johnson & Johnson
Price-to-Book Ratio21.635.57Johnson & Johnson
Debt-to-Equity Ratio756.6564.69Johnson & Johnson
PEG Ratio0.241.07Amgen
EV/EBITDA12.9415.51Amgen
Profit Margin (TTM)18.96%25.00%Johnson & Johnson
Operating Margin (TTM)32.73%28.91%Amgen
EBITDA Margin (TTM)32.73%28.91%Amgen
Return on Equity99.14%30.21%Amgen
Return on Assets (TTM)7.51%7.61%Johnson & Johnson
Free Cash Flow (TTM)$10.39B$18.06BJohnson & Johnson
Dividend Yield4.09%2.47%Amgen
1-Year Return-6.96%16.03%Johnson & Johnson
Price-to-Sales Ratio (TTM)4.604.83Amgen
Enterprise Value$208.88B$469.28BJohnson & Johnson
EV/Revenue Ratio5.985.18Johnson & Johnson
Gross Profit Margin (TTM)67.20%67.87%Johnson & Johnson
Revenue per Share (TTM)$65$38Amgen
Earnings per Share (Diluted)$13.37$9.44Amgen
Beta (Stock Volatility)0.480.39Johnson & Johnson
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Amgen vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

Amgen
Johnson & Johnson
Amgen Stock Overview | Johnson & Johnson Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen-0.37%9.67%3.65%0.19%-2.72%14.70%
Johnson & Johnson-0.04%4.64%4.45%19.56%19.71%29.13%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen-6.96%29.85%25.64%98.81%427.40%286.13%
Johnson & Johnson16.03%16.09%23.19%95.01%194.13%203.20%

News Based Sentiment: Amgen vs Johnson & Johnson

Amgen

News based Sentiment: POSITIVE

Amgen experienced a highly positive month, driven by strong Q2 earnings that exceeded expectations, significant manufacturing investments, positive clinical trial results for Repatha leading to expanded FDA approval, and a subsequent increase in stock price. These factors collectively strengthen the investment case for Amgen.

View Amgen News Sentiment Analysis

Johnson & Johnson

News based Sentiment: POSITIVE

September was a remarkably positive month for Johnson & Johnson, driven by a series of FDA approvals, promising clinical trial results, a significant analyst upgrade, and recognition for sustainability efforts. These developments collectively strengthen the investment case and suggest continued growth potential for the company.

View Johnson & Johnson News Sentiment Analysis

Performance & Financial Health Analysis: Amgen vs Johnson & Johnson

MetricAMGNJNJ
Market Information
Market Cap i$160.11B$437.40B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i3,455,1909,642,260
90 Day Avg. Volume i2,483,1538,329,883
Last Close$297.40$185.98
52 Week Range$253.30 - $335.88$140.68 - $186.59
% from 52W High-11.46%-0.33%
All-Time High$346.85 (Jul 22, 2024)$186.69 (Apr 25, 2022)
% from All-Time High-14.26%-0.38%
Growth Metrics
Quarterly Revenue Growth0.09%0.06%
Quarterly Earnings Growth0.92%0.18%
Financial Health
Profit Margin (TTM) i0.19%0.25%
Operating Margin (TTM) i0.33%0.29%
Return on Equity (TTM) i0.99%0.30%
Debt to Equity (MRQ) i756.6564.69
Cash & Liquidity
Book Value per Share (MRQ)$13.80$32.61
Cash per Share (MRQ)$14.91$7.84
Operating Cash Flow (TTM) i$12.01B$23.03B
Levered Free Cash Flow (TTM) i$10.42B$11.08B
Dividends
Last 12-Month Dividend Yield i4.09%2.47%
Last 12-Month Dividend i$11.64$3.72

Valuation & Enterprise Metrics Analysis: Amgen vs Johnson & Johnson

MetricAMGNJNJ
Price Ratios
P/E Ratio (TTM) i22.3319.24
Forward P/E i14.4417.13
PEG Ratio i0.241.07
Price to Sales (TTM) i4.604.83
Price to Book (MRQ) i21.635.57
Market Capitalization
Market Capitalization i$160.11B$437.40B
Enterprise Value i$208.88B$469.28B
Enterprise Value Metrics
Enterprise to Revenue i5.985.18
Enterprise to EBITDA i12.9415.51
Risk & Other Metrics
Beta i0.480.39
Book Value per Share (MRQ) i$13.80$32.61

Financial Statements Comparison: Amgen vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)AMGNJNJ
Revenue/Sales i$8.15B$23.74B
Cost of Goods Sold i$2.97B$7.63B
Gross Profit i$5.18B$16.12B
Research & Development i$1.49B$3.52B
Operating Income (EBIT) i$1.18B$6.81B
EBITDA i$4.08B$9.21B
Pre-Tax Income i$1.97B$6.49B
Income Tax i$243.00M$954.00M
Net Income (Profit) i$1.73B$5.54B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)AMGNJNJ
Cash & Equivalents i$8.81B$38.47B
Total Current Assets i$26.93B$71.55B
Total Current Liabilities i$23.01B$56.90B
Long-Term Debt i$54.01B$38.36B
Total Shareholders Equity i$6.21B$78.11B
Retained Earnings i$-27.14BN/A
Property, Plant & Equipment iN/AN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)AMGNJNJ
Operating Cash Flow i$1.71B$6.35B
Capital Expenditures i$-411.00M$-795.00M
Free Cash Flow i$980.00M$3.37B
Debt Repayment i$-2.50B$-2.87B
Common Stock Repurchase iN/A$-2.13B

Short Interest & Institutional Ownership Analysis

MetricAMGNJNJ
Shares Short i13.20M22.05M
Short Ratio i6.632.84
Short % of Float i0.02%0.01%
Average Daily Volume (10 Day) i3,455,1909,642,260
Average Daily Volume (90 Day) i2,483,1538,329,883
Shares Outstanding i537.00M2.41B
Float Shares i536.99M2.40B
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.84%0.74%

Dividend Analysis & Yield Comparison: Amgen vs Johnson & Johnson

MetricAMGNJNJ
Last 12-Month Dividend i$11.64$3.72
Last 12-Month Dividend Yield i4.09%2.47%
3-Year Avg Annual Dividend i$9.51$3.97
3-Year Avg Dividend Yield i0.80%0.75%
3-Year Total Dividends i$28.54$11.92
Ex-Dividend DateAug 22, 2025Feb 18, 2025